Copyright
©The Author(s) 2022.
World J Gastroenterol. Nov 7, 2022; 28(41): 5944-5956
Published online Nov 7, 2022. doi: 10.3748/wjg.v28.i41.5944
Published online Nov 7, 2022. doi: 10.3748/wjg.v28.i41.5944
Figure 1 Flow diagram showing the study population and reasons for exclusion from data analysis.
HE: Hepatic encephalopathy; NA: Not available; TIPS: Transjugular intrahepatic portosystemic shunt.
Figure 2 Estimated in-hospital mortality and risk of acute on chronic liver failure depending on liver function.
A and B: Estimated probability of dying in hospital depending on liver function at hospital admission; C and D: Estimated probability of acute on chronic liver failure (ACLF) occurring or existing ACLF worsening, depending on liver function at hospital admission. All probabilities were estimated using a multivariate logistic regression model based on the MELD and Child scores at hospital admission. TIPS: Transjugular intrahepatic portosystemic shunt.
- Citation: Philipp M, Blattmann T, Bienert J, Fischer K, Hausberg L, Kröger JC, Heller T, Weber MA, Lamprecht G. Transjugular intrahepatic portosystemic shunt vs conservative treatment for recurrent ascites: A propensity score matched comparison. World J Gastroenterol 2022; 28(41): 5944-5956
- URL: https://www.wjgnet.com/1007-9327/full/v28/i41/5944.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i41.5944